66 New IHC Antibodies

5 New TintoFast Antibodies

3 New IHC Detection Systems

3 New Multiplex IHC Detection Systems

6 New TMA & CLMA’s

New IHC Ancillaries

New Antibodies for Prostate Cancer Applications

Cyclin D3 (BSB-171), MMab

Expression of Cyclin D3 was significantly associated with Breast Cancer prognosis and was shown to be an independent prognostic marker in Breast Cancer; high Cyclin D3 expression indicates poor disease free survival rate in Breast Cancer.

Read more

New Antibodies for Sarcoma and Soft Tissue Cancer Applications

NUTM1 (RBT-NUTM1), RMab

NUT cancers can be Carcinomas, Sarcomas, Lymphomas, and other types of tumors, and are often formed in the Head, Neck, or Mediastinum.

Read more

SS18-SSX (RBT-SS18-SSX), RMab

Expression of SS18-SSX fusion protein is the hallmark of Synovial Sarcoma, a type of Soft Tissue Sarcoma that accounts for 5-10% of all Soft Tissue Sarcoma.

Read more
STAT6 antibody, stat-6, stat 6, anti stat6, anti stat-6, anti stat 6, anti-stat6, anti-stat-6, anti-stat 6, IL-4 Stat, anti-IL-4 Stat, anti IL-4 Stat, signal transducer and activator of transcription 6 interleukin 4 induced, D12S1644, IL 4 STAT, STAT6B, STAT6C, rabbit monoclonal for immunohistochemistry IHC

STAT6 (RM473), RMab

The STAT6 antibody is a highly sensitive and specific immunohistochemical marker for Solitary Fibrous Tumor and can be helpful to distinguish this tumor type from histologic mimics.

Read more

TLE1 (RBT-TLE1), RMab

TLE1 antibody can be used to differentiate Synovial Sarcoma from other Sarcomas, including histologically similar tumors such as Malignant Peripheral Nerve Sheath Tumor.

Read more

Tri-Methyl-Histone H3(Lys27)/H3K27Me3 (RBT-H3K27Me3), RMab

Loss of H3K27me3 occurs in a significant subset of Malignant Peripheral Nerve Sheath tumors. Other neoplasms may show loss of H3K27me3 expression, such as Meningioma, Radiation Associated Unclassified Sarcoma, Radiation-Associated Angiosarcoma, Dedifferentiated Chondrosarcoma, Melanoma and Merkel Cell Carcinoma, amongst others.

Read more

New Antibodies for Hodgkin’s and NHD Lymphoma Applications

New Antibodies for Cervical Cancer Applications

New Antibodies for Melanoma & Skin Cancer Applications

MLH1 (RBT-MLH1), RMab

In a high proportion of patients with microsatellite instability (MSI-H), the MLH1 protein is typically deficient. This protein deficiency is linked to the autosomaldominant condition of Hereditary Non-Polyposis Colon Cancer.

Read more

TORC3 / CRTC3 (BSB-175), MMab

TORC/CRTC proteins help regulate the cell’s response to c-AMP signaling, and are thus important activators in metabolic networks; gain-of-function mutations can contribute to cancer cell survival and proliferation. Metabolic pathway regulation also contributes to the management of conditions such as diabetes and Cancer
cachexia.

Read more

Tri-Methyl-Histone H3(Lys27)/H3K27Me3 (RBT-H3K27Me3), RMab

Loss of H3K27me3 occurs in a significant subset of Malignant Peripheral Nerve Sheath tumors. Other neoplasms may show loss of H3K27me3 expression, such as Meningioma, Radiation Associated Unclassified Sarcoma, Radiation-Associated Angiosarcoma, Dedifferentiated Chondrosarcoma, Melanoma and Merkel Cell Carcinoma, amongst others.

Read more

New Antibodies for Ovarian Cancer Applications

PAX-8 (RM436), RMab

PAX-8 antibody is an important new marker of Ovarian Cancer and a useful marker for the differential diagnoses in Lung and Neck Tumors, or Tumors at distant sites where Primary Lung Carcinoma or Thyroid Carcinoma are possibilities.

Read more

New Antibodies for Germ Cell Cancer Applications

New Antibodies for Infectious Disease Applications

Candida Albicans (RBT-C.alb), RMab

Erythematous lesions can form in the skin and mucosal membranes, and white psuedomembranous lesions can infect the buccal mucosa, palate, tongue, and alveolar ridges (thrush).

Read more

New Antibodies for Mesothelioma Applications

New Antibodies for Kidney & Urothelial Cancer Applications

PAX-8 (RM436), RMab

PAX-8 antibody is an important new marker of Ovarian Cancer and a useful marker for the differential diagnoses in Lung and Neck Tumors, or Tumors at distant sites where Primary Lung Carcinoma or Thyroid Carcinoma are possibilities.

Read more

DDR1 (BSB-173), MMab

Increased expression of DDR1 has been documented in several types of cancer and fibrotic conditions including Skin Hypertrophic Scars, Idiopathic Pulmonary Fibrosis, Cirrhotic Liver and Renal Fibrosis.

Read more

CEACAM7 (BSB-168), MMab

Compared to other widely expressed CEA family members, expression of CEACAM7 protein is confined to the apical surface of pancreatic ductal cells and epithelial cells of the adult colon tissue. In fetal colon tissues, CEACAM7 is located at the base of epithelial cells but migrates to the apical surface after birth.

Read more

New Antibodies for Leukemia & Histiocytic Cancer Applications

TORC3 / CRTC3 (BSB-175), MMab

TORC/CRTC proteins help regulate the cell’s response to c-AMP signaling, and are thus important activators in metabolic networks; gain-of-function mutations can contribute to cancer cell survival and proliferation. Metabolic pathway regulation also contributes to the management of conditions such as diabetes and Cancer
cachexia.

Read more

New Antibodies for Thyroid and Parathyroid Cancer Applications

Cyclin D3 (BSB-171), MMab

Expression of Cyclin D3 was significantly associated with Breast Cancer prognosis and was shown to be an independent prognostic marker in Breast Cancer; high Cyclin D3 expression indicates poor disease free survival rate in Breast Cancer.

Read more

PAX-8 (RM436), RMab

PAX-8 antibody is an important new marker of Ovarian Cancer and a useful marker for the differential diagnoses in Lung and Neck Tumors, or Tumors at distant sites where Primary Lung Carcinoma or Thyroid Carcinoma are possibilities.

Read more

New Antibodies for Colon & GI Cancer Applications

MUC1 (RBT-MUC1), RMab

MUC1 antibody expression is seen in lactating mammary glands and overexpressed in more than 90% Breast Carcinomas and metastases.

Read more

MLH1 (RBT-MLH1), RMab

In a high proportion of patients with microsatellite instability (MSI-H), the MLH1 protein is typically deficient. This protein deficiency is linked to the autosomaldominant condition of Hereditary Non-Polyposis Colon Cancer.

Read more

LRG1 (BSB-174), MMab

Immunohistochemistry on tissue sections demonstrated that alveolar epithelial cells, renal tubular epithelial cells and interstitial cells express LRG1 in the lung, kidney and heart respectively, while cell-specific loss of function in vivo experiments showed that fibroblasts may represent a key source of LRG1 in the normal skin.

Read more

New Antibodies for Gall Bladder & Pancreatic Cancer Applications

New Antibodies for Head and Neck Cancer Applications

NUTM1 (RBT-NUTM1), RMab

NUT cancers can be Carcinomas, Sarcomas, Lymphomas, and other types of tumors, and are often formed in the Head, Neck, or Mediastinum.

Read more

New Antibodies for Lymphoma Applications

NUTM1 (RBT-NUTM1), RMab

NUT cancers can be Carcinomas, Sarcomas, Lymphomas, and other types of tumors, and are often formed in the Head, Neck, or Mediastinum.

Read more

Tri-Methyl-Histone H3(Lys27)/H3K27Me3 (RBT-H3K27Me3), RMab

Loss of H3K27me3 occurs in a significant subset of Malignant Peripheral Nerve Sheath tumors. Other neoplasms may show loss of H3K27me3 expression, such as Meningioma, Radiation Associated Unclassified Sarcoma, Radiation-Associated Angiosarcoma, Dedifferentiated Chondrosarcoma, Melanoma and Merkel Cell Carcinoma, amongst others.

Read more

New Antibodies for GIST Applications

<< Back to New Products Page 1